中华核医学杂志
中華覈醫學雜誌
중화핵의학잡지
CHINESE JOURNAL OF NUCLEAR MEDICINE
2008年
4期
244-246
,共3页
武婕%王峰%杨敏%王自正%孟庆乐%过燕萍
武婕%王峰%楊敏%王自正%孟慶樂%過燕萍
무첩%왕봉%양민%왕자정%맹경악%과연평
帕金森病%受体,多巴胺%体层摄影术,发射型计算机,单光子%Epidepride
帕金森病%受體,多巴胺%體層攝影術,髮射型計算機,單光子%Epidepride
파금삼병%수체,다파알%체층섭영술,발사형계산궤,단광자%Epidepride
Parkinson disease%Receptors,dopamine%Tomography,emission-computed,single-photon%Epidepride
目的 评价多巴胺D2受体显像剂131I-(s)-(-)-N-[(1-乙基-2-吡咯烷基)甲基]-5-碘-2,3-二甲氧基苯甲酰胺(epidepride)对帕金森病(PD)的临床应用价值.方法 PD患者38例(H/YⅠ~Ⅳ级,病程4个月~6年),健康对照组12例,静脉注射131I-epidepride 18.5 MBq 3 h后行SPECT显像,并应用感兴趣区(ROI)技术计算纹状体/枕叶放射性(ST/OC)比值,分析ST/OC比值与PD患者临床严重程度的相关性.采用SPSS 10.0软件对数据进行校正t检验,配对t检验及Spearman相关分析.结果 对照组131I-epidepride显像示双侧纹状体内有高度放射性浓聚,纹状体显示清晰,双侧基本对称,额叶、颞叶、顶叶、枕叶及小脑放射性较低.与健康对照组比较,PD患者ST内131I-epide-pride浓聚增加,但差异无统计学意义.早期PD患者(H/Y Ⅰ级)病侧肢体的对侧ST放射性显著增加、体积增大(壳核尤为显著),与同侧ST相比差异有统计学意义(t=7.89,P<0.05).ST/OC比值与PD临床严重程度(H/Y分级)无明显相关性(r=0.12,P>0.05).结论 多巴胺D2受体131I-Epi-depride SPECT显像有助于了解PD患者ST内突触后膜的多巴胺D2受体变化,PD患者D2上调,在偏侧PD中以病变对侧壳核尤为显著.ST/OC比值与PD临床严重程度无相关性.
目的 評價多巴胺D2受體顯像劑131I-(s)-(-)-N-[(1-乙基-2-吡咯烷基)甲基]-5-碘-2,3-二甲氧基苯甲酰胺(epidepride)對帕金森病(PD)的臨床應用價值.方法 PD患者38例(H/YⅠ~Ⅳ級,病程4箇月~6年),健康對照組12例,靜脈註射131I-epidepride 18.5 MBq 3 h後行SPECT顯像,併應用感興趣區(ROI)技術計算紋狀體/枕葉放射性(ST/OC)比值,分析ST/OC比值與PD患者臨床嚴重程度的相關性.採用SPSS 10.0軟件對數據進行校正t檢驗,配對t檢驗及Spearman相關分析.結果 對照組131I-epidepride顯像示雙側紋狀體內有高度放射性濃聚,紋狀體顯示清晰,雙側基本對稱,額葉、顳葉、頂葉、枕葉及小腦放射性較低.與健康對照組比較,PD患者ST內131I-epide-pride濃聚增加,但差異無統計學意義.早期PD患者(H/Y Ⅰ級)病側肢體的對側ST放射性顯著增加、體積增大(殼覈尤為顯著),與同側ST相比差異有統計學意義(t=7.89,P<0.05).ST/OC比值與PD臨床嚴重程度(H/Y分級)無明顯相關性(r=0.12,P>0.05).結論 多巴胺D2受體131I-Epi-depride SPECT顯像有助于瞭解PD患者ST內突觸後膜的多巴胺D2受體變化,PD患者D2上調,在偏側PD中以病變對側殼覈尤為顯著.ST/OC比值與PD臨床嚴重程度無相關性.
목적 평개다파알D2수체현상제131I-(s)-(-)-N-[(1-을기-2-필각완기)갑기]-5-전-2,3-이갑양기분갑선알(epidepride)대파금삼병(PD)적림상응용개치.방법 PD환자38례(H/YⅠ~Ⅳ급,병정4개월~6년),건강대조조12례,정맥주사131I-epidepride 18.5 MBq 3 h후행SPECT현상,병응용감흥취구(ROI)기술계산문상체/침협방사성(ST/OC)비치,분석ST/OC비치여PD환자림상엄중정도적상관성.채용SPSS 10.0연건대수거진행교정t검험,배대t검험급Spearman상관분석.결과 대조조131I-epidepride현상시쌍측문상체내유고도방사성농취,문상체현시청석,쌍측기본대칭,액협、섭협、정협、침협급소뇌방사성교저.여건강대조조비교,PD환자ST내131I-epide-pride농취증가,단차이무통계학의의.조기PD환자(H/Y Ⅰ급)병측지체적대측ST방사성현저증가、체적증대(각핵우위현저),여동측ST상비차이유통계학의의(t=7.89,P<0.05).ST/OC비치여PD림상엄중정도(H/Y분급)무명현상관성(r=0.12,P>0.05).결론 다파알D2수체131I-Epi-depride SPECT현상유조우료해PD환자ST내돌촉후막적다파알D2수체변화,PD환자D2상조,재편측PD중이병변대측각핵우위현저.ST/OC비치여PD림상엄중정도무상관성.
Objective Epidepride is a novel benzamide derivative with high affinity for dopaminergic D2 receptors.It has been used to study striatal and extrastriatal D2 receptor abnormalities in humans.The aim of this study was to evaluate the level of D2 receptors in dopaminergic nitrostriatal pathway and its correlation with clinical severity in Parkinson's disease(PD).Methods Thirty-eight patients with idio-pathic PD[graded according to Hoehn and Yahr(H/Y)stage:n(Ⅰ)=13,n(Ⅱ)=11,n(Ⅲ)=8,n(Ⅳ)=6]and 12 healthy volunteers as control were included in this study.SPECT brain imaging was performed 3 h after 18.5 MBq 131I-epidepride administration.Regions of interest(ROIs)were drawn over the striatum(ST)and occipital cortex(OC).The ratios of ST to OC ROI counts(ST/OC)were calculated and correlated with clinical severity H/Y stage.SPSS 10.0 was used for data analysis,the t test and Spearman correlation analysis were used.Results ST showed intense uptake of 131I-epidepride,whereas frontal,parietal,temporal,occipital lobes and cerebellum showed low uptake in control group.Increased 131I-epide-pride uptake was observed in PD patients when compared with normal control group but without statistically significant difference.Early stage patients(hemi-PD with H/Y I)showed increased [131]I-epidepride uptake intensity and size in contralateral ST(especially caudate nucleus)significantly more than unilateral ST(t=7.89.P<0.05).ST/OC ratio was not found to be statistically significant when correlated with the clinical severity H/Y stage(r=0.1 2,P>0.05).Conclusions This study suggested that 131I-epidepride SPECT was useful in qualitative and quantitative evaluation of D2 receptor status in dopaminergic nigrostriatal neurons,which were over-expressed in PD patients.However,no statistically significant correlation was,found between ST 131I-epidepride binding ratios and disease severity.